Last reviewed · How we verify

Zolpidem (Myslee®) — Competitive Intelligence Brief

Zolpidem (Myslee®) (Zolpidem (Myslee®)) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Selective benzodiazepine receptor agonist (non-benzodiazepine hypnotic). Area: Neurology / Sleep Medicine.

marketed Selective benzodiazepine receptor agonist (non-benzodiazepine hypnotic) GABA-A receptor (alpha-1 subunit selective) Neurology / Sleep Medicine Small molecule Live · refreshed every 30 min

Target snapshot

Zolpidem (Myslee®) (Zolpidem (Myslee®)) — Astellas Pharma Inc. Zolpidem is a selective benzodiazepine receptor agonist that enhances inhibitory GABA signaling in the central nervous system to promote sleep onset.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Zolpidem (Myslee®) TARGET Zolpidem (Myslee®) Astellas Pharma Inc marketed Selective benzodiazepine receptor agonist (non-benzodiazepine hypnotic) GABA-A receptor (alpha-1 subunit selective)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Selective benzodiazepine receptor agonist (non-benzodiazepine hypnotic) class)

  1. Astellas Pharma Inc · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Zolpidem (Myslee®) — Competitive Intelligence Brief. https://druglandscape.com/ci/zolpidem-myslee. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: